Abstract:We investigated the interplay between immunosuppressive TGFβ signaling and immunogenic DNA repair in response to immune checkpoint inhibition (ICI) in a new model of breast cancer. Transforming growth factor beta (TGFβ) is a canonical suppressor. Cancer cells evade TGFβ either by selectively overcoming TGFβ proliferative barrier or completely shutting down signaling. Loss of TGFβ signaling is accompanied by high immunosuppressive TGFβ activity. We have shown that loss of TGFβ is critical to genomic integrity. It endorses classical DNA repair and inhibits error-prone repair. We described a score, βAlt, that reports the TGFβ/DNA repair functional relationship. Pan-cancer analysis showed that high βAlt cancers, in which the TGFβ target signature is low and DNA repair signature is high, use error-prone DNA repair, are sensitive to chemoradiation and have a greater fraction of the genome altered compared to low βAlt cancers, which maintain TGFβ signaling. We established a novel murine tumor derived transplant model (mTDT) of triple-negative breast cancer, similar to a human PDX, in immunocompetent BALB/cJ mice. Transcriptomics analysis showed that mTDT range from high to low βAlt and from immune poor to immune rich, which was confirmed by multiplex immunstaining. Unsupervised clustering of mTDT based on βAlt score demonstrated that low βAlt was associated with immune rich tumors while high βAlt was associated with immune poor tumors. A similar relationship is evident in the TCGA breast cancers. We then asked how mTDT respond to ICI. Mice bearing mTDT were randomized to monotherapy consisting of single fraction 10 Gy radiation, anti-PD-L1 or TGFβ inhibition, dual or triple treatment. Neither anti-PD-L1 or TGFβ inhibition affected survival, alone or in combination, whereas radiation significantly increased survival. Unexpectedly immune poor, high βAlt mTDT were the most responsive. To evaluate biological correlates, mice were stratified as a function of treatment as responders, in which tumor growth was controlled for 7 days post-treatment, or non-responders, in which tumor growth was uncontrolled. Tumor infiltrating CD45+ cells increased (P=0.02) as did circulating CD8 T cells (P<0.001) in responders. Natural killer (NK) cells were also significantly expanded in responders (P<0.001). TGFβ broadly downregulates chemokine receptor expression necessary to recruit NK cells and impairs NK cell cytotoxic effector function. We depleted NK cells to test whether they were necessary for the pronounced response to triple treatment. NK depletion was completely abrogated response (P<0.00001) indicating NK cells can provoke an ICI response in high βAlt mammary tumors devoid of lymphocytes. This preclinical model and human breast cancer shows that loss of TGFβ signaling resulting in error-prone DNA damage response is strongly associated with immune poor tumors, and suggests that TGFβ inhibition can override NK cell dysfunction to create vulnerability to ICI and anti-tumor immunity. Citation Format: Jade Moore, Jim Gkantalis, Ines Guix, Colin Foster, Mary Helen Barcellos-Hoff. Compromised TGFβ signaling and DNA repair primes response to immune checkpoint inhibition by activating NK cells in immunologically cold breast cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr B032.

TGFβ Regulates NK1R-Tr to Affect the Proliferation and Apoptosis of Breast Cancer Cells

MiR-34b/c-5p and the Neurokinin-1 Receptor Regulate Breast Cancer Cell Proliferation and Apoptosis

Effect of truncated neurokinin-1 receptor expression changes on the interaction between human breast cancer and bone marrow-derived mesenchymal stem cells.

Gr-1+Cd11b+Cells Are Responsible For Tumor Promoting Effect Of Tgf-Ss In Breast Cancer Progression

The killing effect of Tanshinol on breast cancer cells: insight into the reversion of TGF-β1-mediated suppression of NK cell functions

Nuclear Receptor NR4A1 Promotes Breast Cancer Invasion and Metastasis by Activating TGF-β Signalling

Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer

Neurokinin-1 Activation Affects EGFR Related Signal Transduction in Triple Negative Breast Cancer.

TGF-β1 expression in regulatory NK1.1-CD4+NKG2D+ T cells dependents on the PI3K-p85α/JNK, NF-κB and STAT3 pathways

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer

Effect of Fractalkine, IP-10 and Different Signal Pathway Inhibitors on NK Cells in the Tumor Microenvironment

Tropomyosin-related Kinase C Regulating the Biological Characteristics of Breast Cancer Cell T47D As a Dependence Receptor

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

The Prognostic Role of TGF-β Signaling Pathway in Breast Cancer Patients.

Increased circulating TGF-β1 is associated with impairment in NK cell effector functions in metastatic melanoma patients

PGR-KITLG Signaling Drives a Tumor-Mast Cell Regulatory Feedback to Modulate Apoptosis of Breast Cancer Cells

Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer

TGF-β Induced Reprogramming and Drug Resistance in Triple-Negative Breast Cells

TGF‐β Regulates the Proliferation of Lung Adenocarcinoma Cells by Inhibiting PIK3R3 Expression

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis

Abstract B032: Compromised TGFβ signaling and DNA repair primes response to immune checkpoint inhibition by activating NK cells in immunologically cold breast cancers